Figure 5
Figure 5. Serum VEGF and Ang2 are increased in acute SCLS. (A-F) Serum VEGF (A), Ang2 (B), TNFα (C), plasma Ang1 (D), serum soluble VEGFR2 (E), or serum soluble Tie2 (F) in patients with SCLS without symptoms (“basal”), during acute attacks (“episodic”), or healthy controls without SCLS were determined by ELISA. Horizontal bars depict the median value. (A-B) P < .0003, Kruskal-Wallis test for all across-group comparisons; *P < .05; **P < .005; and ***P < .0005, Dunn posttest.

Serum VEGF and Ang2 are increased in acute SCLS. (A-F) Serum VEGF (A), Ang2 (B), TNFα (C), plasma Ang1 (D), serum soluble VEGFR2 (E), or serum soluble Tie2 (F) in patients with SCLS without symptoms (“basal”), during acute attacks (“episodic”), or healthy controls without SCLS were determined by ELISA. Horizontal bars depict the median value. (A-B) P < .0003, Kruskal-Wallis test for all across-group comparisons; *P < .05; **P < .005; and ***P < .0005, Dunn posttest.

Close Modal

or Create an Account

Close Modal
Close Modal